Hoth Therapeutics (NASDAQ:HOTH) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Hoth Therapeutics (NASDAQ:HOTH) announced its quarterly earnings data on Friday. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07, Zacks reports.

Hoth Therapeutics Trading Up 3.0 %

Shares of HOTH traded up $0.03 during trading hours on Friday, hitting $1.03. The company had a trading volume of 131,058 shares, compared to its average volume of 9,210,386. Hoth Therapeutics has a one year low of $0.58 and a one year high of $3.80. The company’s fifty day moving average price is $1.14 and its two-hundred day moving average price is $1.01. The company has a market capitalization of $7.11 million, a PE ratio of -0.78 and a beta of 0.84.

Analyst Ratings Changes

Several research firms have recently weighed in on HOTH. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a research note on Thursday, January 23rd. D. Boral Capital reiterated a “buy” rating and issued a $5.00 target price on shares of Hoth Therapeutics in a report on Monday, March 10th.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.